Publications by authors named "Julie N Graff"

45Publications

Leveraging Veterans Health Administration Clinical and Research Resources to Accelerate Discovery and Testing in Precision Oncology.

Fed Pract 2020 Aug;37(Suppl 4):S62-S67

is Section Chief of Hematology/Oncology at VA Portland Health Care System in Oregon. is Acting Deputy Chief Research and Development - Enterprise Optimization and Director, Cooperative Studies Program in the Office of Research and Development, Veterans Health Administration, U.S. Department of Veterans Affairs, Washington, DC. Julie Graff is also an Associate Professor of Medicine at Knight Cancer Institute, Oregon Health Sciences University in Portland.

View Article and Find Full Text PDF
August 2020

Immunotherapy in Prostate Cancer.

Cancers (Basel) 2020 Jul 1;12(7). Epub 2020 Jul 1.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.

View Article and Find Full Text PDF
July 2020

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

N Engl J Med 2018 Apr 8;378(15):1408-1418. Epub 2018 Feb 8.

From the Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (M.R.S.); Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal (F.S.); Guy's, King's and St. Thomas' Hospitals, Great Maze Pond, London (S.C.); Georges Pompidou Hospital, Paris (S.O.); University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany (B.A.H.); Veterans Affairs Portland Health Care System, Portland, and Knight Cancer Institute, Oregon Health and Science University, Portland (J.N.G.); Spanish National Cancer Research Center, Madrid, and Hospitales Universitarios Virgen de la Victoria y Regional, Institute of Biomedical Research in Malaga, Malaga - both in Spain (D.O.); Centre for Personalised Nanomedicine, University of Queensland, Brisbane, Australia (P.N.M.); St. Mary's Hospital of Catholic University, Seoul, South Korea (J.Y.L.); Yokohama City University Medical Center, Yokohama, Japan (H.U.); Janssen Research and Development, Los Angeles (A.L.-G., G.C.T., B.M.E., Y.S., Y.C.P., W.R.R., M.K.Y.); and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco (E.J.S.).

View Article and Find Full Text PDF
April 2018

Predictors of response and resistance to checkpoint inhibitors in solid tumors.

Ann Transl Med 2017 Dec;5(23):468

VA Portland Health Care System, Portland, OR, USA.

View Article and Find Full Text PDF
December 2017

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.

Sci Adv 2017 May 17;3(5):e1602133. Epub 2017 May 17.

Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.

View Article and Find Full Text PDF
May 2017

Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making.

JCO Precis Oncol 2017 28;1. Epub 2017 Jun 28.

Derrick L. Tao, Shawna Bailey, Tomasz M. Beer, Erik Foss, Brooke Beckett, Alice Fung, Bryan R. Foster, Alexander Guimaraes, Jeremy P. Cetnar, Julie N. Graff, Kristine M. Eilers, Christopher L. Corless, George V. Thomas, and Joshi J. Alumkal, Oregon Health & Science University, Portland, OR; and Eric J. Small, University of California, San Francisco, San Francisco, CA.

View Article and Find Full Text PDF
June 2017

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.

Res Rep Urol 2016 29;8:217-224. Epub 2016 Nov 29.

Knight Cancer Institute, Oregon Health & Science University; VA Portland Health Care System, Portland, OR, USA.

View Article and Find Full Text PDF
November 2016